{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:23:57Z","timestamp":1768908237411,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant pleural effusion (MPE) confers dismal prognosis and has limited treatment options. While immune-checkpoint inhibition (ICI) proved clinical efficacy in a variety of malignancies, data on the prognostic role of PD-L1 in MPE is scarce. We retrospectively studied PD-L1 tumour proportion score and Ki-67 index in pleural biopsies or cytologies from 123 patients (69 lung cancer, 25 mesothelioma, and 29 extrathoracic primary malignancies). Additionally, the impact of C-reactive protein (CRP) and platelet count was also analysed. Median overall survival (OS) after MPE diagnosis was 9 months. Patients with PD-L1 positive tumours (\u22651%) had significantly shorter OS than patients with negative PD-L1 status (p\u2009=\u20090.031). CRP and Ki-67 index were also prognostic and remained independent prognosticators after multivariate analysis. Interestingly, Ki-67 index and CRP influenced the prognostic power of PD-L1. Finally, patients receiving ICI tended to have a longer median OS and CRP - but not PD-L1 - was a significant prognosticator in this subgroup. In summary, histological and circulating biomarkers should also be taken into account as potential biomarkers in ICI therapy and they may have an impact on the prognostic power of PD-L1. Our findings might help personalizing immune-checkpoint inhibition for patients with MPE and warrant further prospective validation.<\/jats:p>","DOI":"10.1038\/s41598-020-62813-2","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T10:03:09Z","timestamp":1585735389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition"],"prefix":"10.1038","volume":"10","author":[{"given":"Bahil","family":"Ghanim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rosenmayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Stockhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Celik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aynur","family":"Bas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail Cuneyt","family":"Kurul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nalan","family":"Akyurek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Pl\u00f6nes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Bankfalvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Hackner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Errhalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Scheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Seebacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balazs","family":"Hegedus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Stubenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"issue":"Suppl 2","key":"62813_CR1","doi-asserted-by":"publisher","first-page":"ii32","DOI":"10.1136\/thx.2010.136994","volume":"65","author":"ME Roberts","year":"2010","unstructured":"Roberts, M. E. et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 65(Suppl 2), ii32\u201340, https:\/\/doi.org\/10.1136\/thx.2010.136994 (2010).","journal-title":"Thorax"},{"key":"62813_CR2","doi-asserted-by":"publisher","unstructured":"Bibby, A. C. et al. ERS\/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg, https:\/\/doi.org\/10.1093\/ejcts\/ezy258 (2018).","DOI":"10.1093\/ejcts\/ezy258"},{"key":"62813_CR3","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1470-2045(18)30294-8","volume":"19","author":"I Psallidas","year":"2018","unstructured":"Psallidas, I. et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol. 19, 930\u2013939, https:\/\/doi.org\/10.1016\/S1470-2045(18)30294-8 (2018).","journal-title":"Lancet Oncol."},{"key":"62813_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","volume":"69","author":"AO Clive","year":"2014","unstructured":"Clive, A. O. et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 69, 1098\u20131104, https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205285 (2014).","journal-title":"Thorax"},{"key":"62813_CR5","doi-asserted-by":"publisher","first-page":"e0200341","DOI":"10.1371\/journal.pone.0200341","volume":"13","author":"JU Lim","year":"2018","unstructured":"Lim, J. U. et al. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. PLoS One 13, e0200341, https:\/\/doi.org\/10.1371\/journal.pone.0200341 (2018).","journal-title":"PLoS One"},{"key":"62813_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/crj.12292","volume":"10","author":"US Kasapoglu","year":"2016","unstructured":"Kasapoglu, U. S. et al. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions. Clin. Respir. J. 10, 791\u2013799, https:\/\/doi.org\/10.1111\/crj.12292 (2016).","journal-title":"Clin. Respir. J."},{"key":"62813_CR7","doi-asserted-by":"publisher","unstructured":"Bibby, A. C. et al. ERS\/EACTS statement on the management of malignant pleural effusions. Eur Respir J 52, https:\/\/doi.org\/10.1183\/13993003.00349-2018 (2018).","DOI":"10.1183\/13993003.00349-2018"},{"key":"62813_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373, 1627\u20131639, https:\/\/doi.org\/10.1056\/NEJMoa1507643 (2015).","journal-title":"N. Engl. J. Med."},{"key":"62813_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Sci. 342, 1432\u20131433, https:\/\/doi.org\/10.1126\/science.342.6165.1432 (2013).","journal-title":"Cancer immunotherapy. Sci."},{"key":"62813_CR10","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/annonc\/mds647","volume":"24","author":"C Zielinski","year":"2013","unstructured":"Zielinski, C., Knapp, S., Mascaux, C. & Hirsch, F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann. Oncol. 24, 1170\u20131179, https:\/\/doi.org\/10.1093\/annonc\/mds647 (2013).","journal-title":"Ann. Oncol."},{"key":"62813_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-018-0330-4","volume":"120","author":"N Halama","year":"2019","unstructured":"Halama, N. The next age of immunotherapy: optimisation, stratification and therapeutic synergies. Br. J. Cancer 120, 1\u20132, https:\/\/doi.org\/10.1038\/s41416-018-0330-4 (2019).","journal-title":"Br. J. Cancer"},{"key":"62813_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jtho.2017.10.034","volume":"13","author":"YH Tseng","year":"2018","unstructured":"Tseng, Y. H. et al. PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion. J. Thorac. Oncol. 13, 447\u2013453, https:\/\/doi.org\/10.1016\/j.jtho.2017.10.034 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"62813_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/1759-7714.13004","volume":"10","author":"R Shibaki","year":"2019","unstructured":"Shibaki, R. et al. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. Thorac. Cancer 10, 815\u2013822, https:\/\/doi.org\/10.1111\/1759-7714.13004 (2019).","journal-title":"Thorac. Cancer"},{"key":"62813_CR14","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","volume":"13","author":"Y Metaxas","year":"2018","unstructured":"Metaxas, Y. et al. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. J. Thorac. Oncol. 13, 1784\u20131791, https:\/\/doi.org\/10.1016\/j.jtho.2018.08.007 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"62813_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/SLA.0b013e3182602af4","volume":"256","author":"B Ghanim","year":"2012","unstructured":"Ghanim, B. et al. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. Ann. Surg. 256, 357\u2013362, https:\/\/doi.org\/10.1097\/SLA.0b013e3182602af4 (2012).","journal-title":"Ann. Surg."},{"key":"62813_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/bjc.2013.815","volume":"110","author":"B Ghanim","year":"2014","unstructured":"Ghanim, B. et al. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. Br. J. Cancer 110, 984\u2013990, https:\/\/doi.org\/10.1038\/bjc.2013.815 (2014).","journal-title":"Br. J. Cancer"},{"key":"62813_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/bjc.2015.9","volume":"112","author":"B Ghanim","year":"2015","unstructured":"Ghanim, B. et al. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. Br. J. Cancer 112, 783\u2013792, https:\/\/doi.org\/10.1038\/bjc.2015.9 (2015).","journal-title":"Br. J. Cancer"},{"key":"62813_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16551-7","volume":"7","author":"T Klikovits","year":"2017","unstructured":"Klikovits, T. et al. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Sci. Rep. 7, 16456, https:\/\/doi.org\/10.1038\/s41598-017-16551-7 (2017).","journal-title":"Sci. Rep."},{"key":"62813_CR19","doi-asserted-by":"publisher","first-page":"21861","DOI":"10.18632\/oncotarget.25076","volume":"9","author":"S Janik","year":"2018","unstructured":"Janik, S. et al. Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome. Oncotarget 9, 21861\u201321875, https:\/\/doi.org\/10.18632\/oncotarget.25076 (2018).","journal-title":"Oncotarget"},{"key":"62813_CR20","doi-asserted-by":"publisher","first-page":"47090","DOI":"10.18632\/oncotarget.17478","volume":"8","author":"S Janik","year":"2017","unstructured":"Janik, S. et al. Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis. Oncotarget 8, 47090\u201347102, https:\/\/doi.org\/10.18632\/oncotarget.17478 (2017).","journal-title":"Oncotarget"},{"key":"62813_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12914-2","volume":"7","author":"B Ghanim","year":"2017","unstructured":"Ghanim, B. et al. Intrathoracic solitary fibrous tumor - an international multicenter study on clinical outcome and novel circulating biomarkers. Sci. Rep. 7, 12557, https:\/\/doi.org\/10.1038\/s41598-017-12914-2 (2017).","journal-title":"Sci. Rep."},{"key":"62813_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/icvts\/ivv206","volume":"21","author":"B Ghanim","year":"2015","unstructured":"Ghanim, B. et al. Elevated inflammatory parameters and inflammation scores are associated with poor prognosis in patients undergoing pulmonary metastasectomy for colorectal cancer. Interact. Cardiovasc. Thorac. Surg. 21, 616\u2013623, https:\/\/doi.org\/10.1093\/icvts\/ivv206 (2015).","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"62813_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2217\/imt-2019-0039","volume":"11","author":"A Schiwitza","year":"2019","unstructured":"Schiwitza, A. et al. Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Immunotherapy 11, 769\u2013782, https:\/\/doi.org\/10.2217\/imt-2019-0039 (2019).","journal-title":"Immunotherapy"},{"key":"62813_CR24","doi-asserted-by":"publisher","first-page":"103117","DOI":"10.18632\/oncotarget.21602","volume":"8","author":"Y Oya","year":"2017","unstructured":"Oya, Y. et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget 8, 103117\u2013103128, https:\/\/doi.org\/10.18632\/oncotarget.21602 (2017).","journal-title":"Oncotarget"},{"key":"62813_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/modpathol.2011.146","volume":"25","author":"K Kadota","year":"2012","unstructured":"Kadota, K. et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod. Pathol. 25, 260\u2013271, https:\/\/doi.org\/10.1038\/modpathol.2011.146 (2012).","journal-title":"Mod. Pathol."},{"key":"62813_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2012.10.008","volume":"79","author":"JN Jakobsen","year":"2013","unstructured":"Jakobsen, J. N. & Sorensen, J. B. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer 79, 1\u20137, https:\/\/doi.org\/10.1016\/j.lungcan.2012.10.008 (2013).","journal-title":"Lung Cancer"},{"key":"62813_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","volume":"11","author":"R Yerushalmi","year":"2010","unstructured":"Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M. & Gelmon, K. A. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11, 174\u2013183, https:\/\/doi.org\/10.1016\/S1470-2045(09)70262-1 (2010).","journal-title":"Lancet Oncol."},{"key":"62813_CR28","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.18632\/oncotarget.23580","volume":"9","author":"X Xiang","year":"2018","unstructured":"Xiang, X. et al. Prognostic value of PD -L1 expression in patients with primary solid tumors. Oncotarget 9, 5058\u20135072, https:\/\/doi.org\/10.18632\/oncotarget.23580 (2018).","journal-title":"Oncotarget"},{"key":"62813_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29156-5","volume":"8","author":"J Xu","year":"2018","unstructured":"Xu, J. et al. PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: a controlled study by pleural biopsy. Sci. Rep. 8, 11206, https:\/\/doi.org\/10.1038\/s41598-018-29156-5 (2018).","journal-title":"Sci. Rep."},{"key":"62813_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","volume":"105","author":"JS Palumbo","year":"2005","unstructured":"Palumbo, J. S. et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105, 178\u2013185, https:\/\/doi.org\/10.1182\/blood-2004-06-2272 (2005).","journal-title":"Blood"},{"key":"62813_CR31","doi-asserted-by":"publisher","unstructured":"Mukaida, N., Nosaka, T., Nakamoto, Y. & Baba, T. Lung Macrophages: Multifunctional Regulator Cells for Metastatic Cells. Int J Mol Sci 20, https:\/\/doi.org\/10.3390\/ijms20010116 (2018).","DOI":"10.3390\/ijms20010116"},{"key":"62813_CR32","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ijc.29847","volume":"138","author":"N Li","year":"2016","unstructured":"Li, N. Platelets in cancer metastasis: To help the \u201cvillain\u201d to do evil. Int. J. Cancer 138, 2078\u20132087, https:\/\/doi.org\/10.1002\/ijc.29847 (2016).","journal-title":"Int. J. Cancer"},{"key":"62813_CR33","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830, https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7 (2019).","journal-title":"Lancet"},{"key":"62813_CR34","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","volume":"22","author":"L Pai-Scherf","year":"2017","unstructured":"Pai-Scherf, L. et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist 22, 1392\u20131399, https:\/\/doi.org\/10.1634\/theoncologist.2017-0078 (2017).","journal-title":"Oncologist"},{"key":"62813_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck, M. et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J. Clin. Oncol. 37, 537\u2013546, https:\/\/doi.org\/10.1200\/JCO.18.00149 (2019).","journal-title":"J. Clin. Oncol."},{"key":"62813_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2019.06.005","volume":"134","author":"A Haragan","year":"2019","unstructured":"Haragan, A. et al. Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. Lung Cancer 134, 79\u201384, https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.005 (2019).","journal-title":"Lung Cancer"},{"key":"62813_CR37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cllc.2017.04.014","volume":"18","author":"D Casadevall","year":"2017","unstructured":"Casadevall, D. et al. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. Clin. Lung Cancer 18, 682\u2013691 e685, https:\/\/doi.org\/10.1016\/j.cllc.2017.04.014 (2017).","journal-title":"Clin. Lung Cancer"},{"key":"62813_CR38","doi-asserted-by":"publisher","first-page":"90123","DOI":"10.18632\/oncotarget.21485","volume":"8","author":"E Munari","year":"2017","unstructured":"Munari, E. et al. PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. Oncotarget 8, 90123\u201390131, https:\/\/doi.org\/10.18632\/oncotarget.21485 (2017).","journal-title":"Oncotarget"},{"key":"62813_CR39","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/resp.13614","volume":"24","author":"HB Grosu","year":"2019","unstructured":"Grosu, H. B. et al. PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC. Respirology 24, 1198\u20131203, https:\/\/doi.org\/10.1111\/resp.13614 (2019).","journal-title":"Respirology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62813-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62813-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:05:53Z","timestamp":1670317553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-62813-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["62813"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-62813-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]},"assertion":[{"value":"13 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5784"}}